-
1
-
-
33746862566
-
Overview of randomised trials of ACE inhibitors
-
Remuzzi G, Ruggenenti P. Overview of randomised trials of ACE inhibitors. Lancet. 2006;368:555-556.
-
(2006)
Lancet
, vol.368
, pp. 555-556
-
-
Remuzzi, G.1
Ruggenenti, P.2
-
2
-
-
0035922447
-
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
-
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
-
(2001)
N Engl J Med
, vol.345
, pp. 851-860
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Clarke, W.R.3
-
3
-
-
28844504752
-
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis
-
Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026-2033.
-
(2005)
Lancet
, vol.366
, pp. 2026-2033
-
-
Casas, J.P.1
Chua, W.2
Loukogeorgakis, S.3
-
4
-
-
0037165228
-
Angiotensin II and trials of cardiovascular outcomes
-
Sleight P. Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol. 2002;89:11A-16A.
-
(2002)
Am J Cardiol
, vol.89
-
-
Sleight, P.1
-
5
-
-
18544369738
-
The cardiovascular continuum and renin-angiotensin-aldosterone system blockade
-
Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl. 2005;23:S9-S17.
-
(2005)
J Hypertens Suppl
, vol.23
-
-
Dzau, V.1
-
6
-
-
0026762669
-
Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology
-
Israili ZH, Hall W. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-242.
-
(1992)
Ann Intern Med
, vol.117
, pp. 234-242
-
-
Israili, Z.H.1
Hall, W.2
-
7
-
-
0036708218
-
Angiotensin II receptor blocker-associated angioedema: On the heels of ACE inhibitor angioedema
-
Abdi R, Dong VM, Lee CJ, et al. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy. 2002;22:1173-1175.
-
(2002)
Pharmacotherapy
, vol.22
, pp. 1173-1175
-
-
Abdi, R.1
Dong, V.M.2
Lee, C.J.3
-
8
-
-
28344443071
-
-
Tolerability and quality of life in ARB-treated patients
-
Tolerability and quality of life in ARB-treated patients. Am J Manag Care. 2005;11:S392-S394.
-
(2005)
Am J Manag Care
, vol.11
-
-
-
9
-
-
0031937154
-
ACE inhibitor-induced angioedema. Incidence, prevention, and management
-
Vleeming W, Van Amsterdam JG, Stricker BH, de Wilt DJ. ACE inhibitor-induced angioedema. Incidence, prevention, and management. Drug Saf. 1998;18:171-188.
-
(1998)
Drug Saf
, vol.18
, pp. 171-188
-
-
Vleeming, W.1
Van Amsterdam, J.G.2
Stricker, B.H.3
de Wilt, D.J.4
-
10
-
-
0034790379
-
Angioedema associated with angiotensin II receptor antagonists: Challenging our knowledge of angioedema and its etiology
-
Chiu AG, Krowiak EJ, Deeb ZE. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope. 2001;111:1729-1731.
-
(2001)
Laryngoscope
, vol.111
, pp. 1729-1731
-
-
Chiu, A.G.1
Krowiak, E.J.2
Deeb, Z.E.3
-
11
-
-
0028935595
-
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension
-
Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793-795.
-
(1995)
Am J Cardiol
, vol.75
, pp. 793-795
-
-
Goldberg, A.I.1
Dunlay, M.C.2
Sweet, C.S.3
-
12
-
-
0028589122
-
Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group
-
Lacourciere Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. J Hypertens. 1994;12:1387-1393.
-
(1994)
J Hypertens
, vol.12
, pp. 1387-1393
-
-
Lacourciere, Y.1
Brunner, H.2
Irwin, R.3
-
15
-
-
33947732173
-
Brief review: Angiotensin converting enzyme inhibitors and angioedema: anesthetic implications
-
Sarkar P, Nicholson G, Hall G. Brief review: angiotensin converting enzyme inhibitors and angioedema: anesthetic implications. Can J Anaesth. 2006;53:994-1003.
-
(2006)
Can J Anaesth
, vol.53
, pp. 994-1003
-
-
Sarkar, P.1
Nicholson, G.2
Hall, G.3
-
16
-
-
33750583287
-
Angiotensin-converting enzyme inhibitor-associated angioedema
-
Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am. 2006;26:725-737.
-
(2006)
Immunol Allergy Clin North Am
, vol.26
, pp. 725-737
-
-
Byrd, J.B.1
Adam, A.2
Brown, N.J.3
-
17
-
-
29244463522
-
Risk of first-time hospitalization for angioedema among users of ACE inhibitors and angiotensin receptor antagonists
-
Johnsen SP, Jacobsen J, Monster TB, et al. Risk of first-time hospitalization for angioedema among users of ACE inhibitors and angiotensin receptor antagonists. Am J Med. 2005; 118:1428-1429.
-
(2005)
Am J Med
, vol.118
, pp. 1428-1429
-
-
Johnsen, S.P.1
Jacobsen, J.2
Monster, T.B.3
-
18
-
-
0034947385
-
Drug-induced angioedema without urticaria
-
Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf. 2001;24:599-606.
-
(2001)
Drug Saf
, vol.24
, pp. 599-606
-
-
Agostoni, A.1
Cicardi, M.2
-
20
-
-
0038102714
-
Valsartan-induced angioedema
-
Irons BK, Kumar A. Valsartan-induced angioedema. Ann Pharmacother. 2003;37:1024-1027.
-
(2003)
Ann Pharmacother
, vol.37
, pp. 1024-1027
-
-
Irons, B.K.1
Kumar, A.2
-
21
-
-
0034112556
-
Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema
-
Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother. 2000; 34:526-528.
-
(2000)
Ann Pharmacother
, vol.34
, pp. 526-528
-
-
Warner, K.K.1
Visconti, J.A.2
Tschampel, M.M.3
-
22
-
-
1642452758
-
Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial
-
Kostis JB, Packer M, Black HR, et al, Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-111.
-
(2004)
Am J Hypertens
, vol.17
, pp. 103-111
-
-
Kostis, J.B.1
Packer, M.2
Black, H.R.3
-
24
-
-
1942437363
-
Angioedema associated with angiotensin-converting enzyme inhibitor use: Outcome after switching to a different treatment
-
Cicardi M, Zingale LC, Bergamaschini L, et al. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med. 2004;164:910-913.
-
(2004)
Arch Intern Med
, vol.164
, pp. 910-913
-
-
Cicardi, M.1
Zingale, L.C.2
Bergamaschini, L.3
-
25
-
-
0041909380
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: The CHARM-Alternative trial
-
Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-776.
-
(2003)
Lancet
, vol.362
, pp. 772-776
-
-
Granger, C.B.1
McMurray, J.J.2
Yusuf, S.3
-
26
-
-
0038777134
-
The ongoing telmisartan alone and in combination with ramipril global endpoint trial program
-
Unger T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. Am J Cardiol. 2003;91:28G-34G.
-
(2003)
Am J Cardiol
, vol.91
-
-
Unger, T.1
-
27
-
-
28744446343
-
-
Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112:e154-e235.
-
Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112:e154-e235.
-
-
-
-
28
-
-
10944239058
-
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with AcuteMyocardial Infarction)
-
Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with AcuteMyocardial Infarction). Circulation. 2004; 110: e82-e292.
-
(2004)
Circulation
, vol.110
-
-
Antman, E.M.1
Anbe, D.T.2
Armstrong, P.W.3
-
29
-
-
33646828142
-
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute
-
Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006;47:2130-2139.
-
(2006)
J Am Coll Cardiol
, vol.47
, pp. 2130-2139
-
-
Smith Jr, S.C.1
Allen, J.2
Blair, S.N.3
-
30
-
-
3042819708
-
National Heart, Lung, and Blood Institute; Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease
-
AHA; ACC; National Heart, Lung, and Blood Institute; Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 suppl 1):S1-S290.
-
(2004)
Am J Kidney Dis
, vol.43
, Issue.5 SUPPL. 1
-
-
AHA, A.C.C.1
|